MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 91.20M +64.4% |
| Revenue (ttm) | n/a |
| Net Income | -24.25M |
| EPS | -0.66 |
| Shares Out | 60.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,329,930 |
| Open | 1.470 |
| Previous Close | 1.430 |
| Day's Range | 1.440 - 1.560 |
| 52-Week Range | 0.870 - 3.190 |
| Beta | 0.24 |
| Analysts | Strong Buy |
| Price Target | 12.14 (+709.33%) |
| Earnings Date | May 11, 2026 |
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for MAIA stock is "Strong Buy" and the 12-month stock price target is $12.14.
News
MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial
MAIA Biotechnology (MAIA) provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line treatment for advanced n...
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer
MAIA Biotechnology receives FDA clearance for amendment to IND application
MAIA Biotechnology (MAIA) announced that the U.S. Food and Drug Administration has cleared an amendment to update its investigational new drug application which enables MAIA to open U.S. enrollment fo...
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA
MAIA Biotechnology announces open market purchases by CEO, director
MAIA Biotechnology (MAIA) announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan Smith, Ph.D. have increased their ownership positions through open market purchases. Approximately 72,70...
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothera...
MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology
CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunothera...
MAIA Biotechnology Transcript: AGM 2026
The meeting confirmed a quorum, elected two directors for three-year terms, and ratified the appointment of independent auditors. Shareholders participated virtually, with questions addressed during and after the meeting.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on May 19, 2026, providing details for shareholder voting and corporate governance matters.
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)
New York, May 18, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnolo...
MAIA Biotechnology Quarterly report: Q1 2026
MAIA Biotechnology has published its Q1 2026 quarterly earnings report on May 11, 2026.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology secures funding for clinical trial of ateganosine
MAIA Biotechnology (MAIA) announced that net proceeds from its $33M public offering of common stock in March are expected to fully fund the company’s ongoing pivotal Phase 3 clinical trial…
MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Strong participation in recent $33 million common stock offering highlights investor confidence in late-stage clinical momentum and commercial potential
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology Proxy statement: Proxy filing
MAIA Biotechnology filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Potential breakthrough therapeutic targets $50B+ global immunotherapy market 1 CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a cli...
MAIA Biotechnology Annual report: Q4 2025
MAIA Biotechnology has published its Q4 2025 annual report on March 23, 2026.
MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock
Financing included participation by healthcare-dedicated investors alongside existing shareholders CHICAGO, IL, March 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAI...
MAIA Biotechnology 20M share Spot Secondary priced at $1.50
acted as sole book running manager for the offering.
MAIA Biotechnology announces common stock offering, no amount given
MAIA Biotechnology (MAIA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to…
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
CHICAGO, IL, March 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies ...
MAIA Biotechnology published a 2026 Letter to Shareholders
MAIA Biotechnology (MAIA) published a 2026 Letter to Shareholders by Founder and CEO Vlad Vitoc, M.D. featuring the Company’s strong momentum in clinical trials of its lead molecule, ateganosine, as…
MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical success for interim and full analysis
MAIA Biotechnology highlights milestones, catalysts for FY26
Targeted 2026 Milestones: Initial measures of efficacy from Phase 3 study. Interim disease control rates, overall response rates and progression free survival analysis of ateganosine compared to the c...